Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Science Translational Medicine|April 19, 2023
An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humansSarah F Andrews, Lauren Y Cominsky, Geoffrey D Shimberg, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
The New England Journal of Medicine|December 13, 2023
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older AdultsEleanor Wilson, Jaya Goswami, Abdullah H Baqui, et al.
Science Translational Medicine|June 12, 2020
Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody qualitySonia Maciejewski, Tracy J Ruckwardt, Kaitlyn M Morabito, et al.
Science (New York, N.Y.)|August 3, 2019
A proof of concept for structure-based vaccine design targeting RSV in humansMichelle C Crank, Tracy J Ruckwardt, Man Chen, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
Pageof 5